{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T13:52:12Z","timestamp":1793109132823,"version":"4.5.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004337","name":"F Hoffmann-La Roche AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.ejpb.2021.06.001","type":"journal-article","created":{"date-parts":[[2021,6,5]],"date-time":"2021-06-05T21:18:37Z","timestamp":1622927917000},"page":"87-93","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Intraocular pressure and injection forces during intravitreal injection into enucleated porcine eyes"],"prefix":"10.1016","volume":"166","author":[{"given":"Andrea","family":"Allmendinger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuen Li","family":"Butt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.ejpb.2021.06.001_b0005","doi-asserted-by":"crossref","first-page":"e1221","DOI":"10.1016\/S2214-109X(17)30393-5","article-title":"Global causes of blindness and distance vision impairment 1990\u20132020: a systematic review and meta-analysis","volume":"5","author":"Flaxman","year":"2017","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.ejpb.2021.06.001_b0010","unstructured":"Food And Drug Administration. Triesence Label. [cited 2016 March 22]; Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2007\/022223,022048lbl.pdf."},{"key":"10.1016\/j.ejpb.2021.06.001_b0015","unstructured":"Food and Drug Administration. Lucentis label. [cited 2016 March 22]; Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/125156s106lbl.pdf."},{"key":"10.1016\/j.ejpb.2021.06.001_b0020","unstructured":"Food and Drug Administration. Jetrea. [cited 2016 March 22]; Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/125422s025lbl.pdf."},{"key":"10.1016\/j.ejpb.2021.06.001_b0025","unstructured":"Food and Drug Administration. Eylea. [cited 2020 July 05]; Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/125387lbl.pdf."},{"key":"10.1016\/j.ejpb.2021.06.001_b0030","unstructured":"Food and Drug Administration. Beovu. [cited 2020 July 05]; Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/761125s000lbl.pdf."},{"issue":"12","key":"10.1016\/j.ejpb.2021.06.001_b0035","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/j.ophtha.2007.09.012","article-title":"Pharmacokinetics of intravitreal ranibizumab (Lucentis)","volume":"114","author":"Bakri","year":"2007","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.ejpb.2021.06.001_b0040","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0161-6420(02)01969-3","article-title":"Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection","volume":"110","author":"Beer","year":"2003","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.ejpb.2021.06.001_b0045","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.ajo.2004.01.008","article-title":"Serum levels of triamcinolone acetonide after intravitreal injection","volume":"137","author":"Degenring","year":"2004","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"10.1016\/j.ejpb.2021.06.001_b0050","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.ajo.2004.05.028","article-title":"Vitreous concentrations of triamcinolone acetonide in human eyes after intravitreal or subtenon injection","volume":"138","author":"Inoue","year":"2004","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"10.1016\/j.ejpb.2021.06.001_b0055","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.ajo.2003.08.012","article-title":"Intraocular availability of triamcinolone acetonide after intravitreal injection","volume":"137","author":"Jonas","year":"2004","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"10.1016\/j.ejpb.2021.06.001_b0060","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1136\/bjo.80.3.214","article-title":"High dose intravitreal ganciclovir injection provides a prolonged therapeutic intraocular concentration","volume":"80","author":"Morlet","year":"1996","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ejpb.2021.06.001_b0065","doi-asserted-by":"crossref","unstructured":"Bahadorani, S. and M. Singer, Recent advances in the management and understanding of macular degeneration. F1000Res, 2017. 6: p. 519.","DOI":"10.12688\/f1000research.10998.1"},{"issue":"6","key":"10.1016\/j.ejpb.2021.06.001_b0070","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.diabet.2019.04.002","article-title":"Diabetic retinopathy, a vascular and inflammatory disease: Therapeutic implications","volume":"45","author":"Semeraro","year":"2019","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.ejpb.2021.06.001_b0075","unstructured":"ClinicalTrials.gov. A Phase II Study of RBM-007 Alone and RBM-007 With Eylea\u00ae in Subjects With Wet Age-related Macular Degeneration (TOFU). [cited 2020 June 17]; Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04200248?term=RBM-007&cond=Macular+Degeneration&draw=2&rank=2."},{"issue":"5","key":"10.1016\/j.ejpb.2021.06.001_b0080","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/s41433-019-0670-1","article-title":"Faricimab: expanding horizon beyond VEGF","volume":"34","author":"Sharma","year":"2020","journal-title":"Eye (Lond)"},{"issue":"1","key":"10.1016\/j.ejpb.2021.06.001_b0085","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1167\/tvst.9.1.2","article-title":"In Vivo Measurement of the Human Vitreous Chamber Volume Using Computed Tomography Imaging of 100 Eyes","volume":"9","author":"Azhdam","year":"2020","journal-title":"Transl Vis Sci Technol"},{"issue":"1","key":"10.1016\/j.ejpb.2021.06.001_b0090","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1159\/000446878","article-title":"Intraocular Pressure Spikes after Aflibercept Intravitreal Injections","volume":"236","author":"El Chehab","year":"2016","journal-title":"Ophthalmologica"},{"issue":"8","key":"10.1016\/j.ejpb.2021.06.001_b0095","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.jfo.2012.02.009","article-title":"Efficacy of prophylactic treatment of intraocular pressure spikes due to intravitreal injections","volume":"35","author":"El Chehab","year":"2012","journal-title":"J Fr Ophtalmol"},{"issue":"1","key":"10.1016\/j.ejpb.2021.06.001_b0100","doi-asserted-by":"crossref","first-page":"19","DOI":"10.5005\/jp-journals-10008-1132","article-title":"Intraocular Pressure rise after Anti-VEGF Treatment: Prevalence, Possible Mechanisms and Correlations","volume":"7","author":"Kampougeris","year":"2013","journal-title":"J Curr Glaucoma Pract"},{"issue":"6","key":"10.1016\/j.ejpb.2021.06.001_b0105","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.ajo.2008.07.007","article-title":"Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents","volume":"146","author":"Kim","year":"2008","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"10.1016\/j.ejpb.2021.06.001_b0110","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jcjo.2014.11.004","article-title":"Repeated intravitreal anti-vascular endothelial growth factor injections can induce iatrogenic ocular hypertension, especially in patients with open-angle glaucoma","volume":"50","author":"Agard","year":"2015","journal-title":"Can J Ophthalmol"},{"key":"10.1016\/j.ejpb.2021.06.001_b0115","doi-asserted-by":"crossref","first-page":"28","DOI":"10.2174\/1874364101004010028","article-title":"Sustained intraocular pressure elevation after intravitreal injection of bevacizumab and ranibizumab associated with trabeculitis","volume":"4","author":"Sniegowski","year":"2010","journal-title":"Open Ophthalmol J"},{"issue":"2","key":"10.1016\/j.ejpb.2021.06.001_b0120","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.ajo.2014.04.029","article-title":"Predictors of sustained intraocular pressure elevation in eyes receiving intravitreal anti-vascular endothelial growth factor therapy","volume":"158","author":"Yannuzzi","year":"2014","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"10.1016\/j.ejpb.2021.06.001_b0125","doi-asserted-by":"crossref","first-page":"807","DOI":"10.3129\/i07-172","article-title":"Short-term intraocular pressure changes after intravitreal injection of bevacizumab","volume":"42","author":"Hollands","year":"2007","journal-title":"Can J Ophthalmol"},{"issue":"7","key":"10.1016\/j.ejpb.2021.06.001_b0130","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/j.ophtha.2005.10.061","article-title":"Short-term course of intraocular pressure after intravitreal injection of triamcinolone acetonide","volume":"113","author":"Benz","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ejpb.2021.06.001_b0135","doi-asserted-by":"crossref","first-page":"42067","DOI":"10.1038\/srep42067","article-title":"Agreement of patient-measured intraocular pressure using rebound tonometry with Goldmann applanation tonometry (GAT) in glaucoma patients","volume":"7","author":"Tan","year":"2017","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.ejpb.2021.06.001_b0140","first-page":"1389","article-title":"Effect of corneal thickness on intraocular pressure measurements with the pneumotonometer, Goldmann applanation tonometer, and Tono-Pen","volume":"43","author":"Bhan","year":"2002","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ejpb.2021.06.001_b0145","first-page":"525","article-title":"The use of the Sanborn electromanometer in the study of pharmacological effects upon the intraocular pressure","volume":"49","author":"Guerry","year":"1951","journal-title":"Trans Am Soc Ophthalmol Otolaryngol Allergy"},{"issue":"4","key":"10.1016\/j.ejpb.2021.06.001_b0150","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s00417-011-1617-9","article-title":"The parameters of the porcine eyeball","volume":"249","author":"Sanchez","year":"2011","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"3","key":"10.1016\/j.ejpb.2021.06.001_b0155","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.cvfa.2010.09.002","article-title":"Porcine ophthalmology","volume":"26","author":"Middleton","year":"2010","journal-title":"Vet Clin North Am Food Anim Pract"},{"issue":"1","key":"10.1016\/j.ejpb.2021.06.001_b0160","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.clae.2017.09.003","article-title":"Characterisation of the porcine eyeball as an in-vitro model for dry eye","volume":"41","author":"Menduni","year":"2018","journal-title":"Cont Lens Anterior Eye"},{"issue":"1","key":"10.1016\/j.ejpb.2021.06.001_b0165","first-page":"146","article-title":"Reduction of intraocular pressure in mouse eyes treated with latanoprost","volume":"43","author":"Aihara","year":"2002","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"10.1016\/j.ejpb.2021.06.001_b0170","first-page":"249","article-title":"Intraocular pressure in inbred mouse strains","volume":"38","author":"John","year":"1997","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"7","key":"10.1016\/j.ejpb.2021.06.001_b0175","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1007\/s11095-014-1611-0","article-title":"Measuring tissue back-pressure\u2013in vivo injection forces during subcutaneous injection","volume":"32","author":"Allmendinger","year":"2015","journal-title":"Pharm Res"},{"issue":"2","key":"10.1016\/j.ejpb.2021.06.001_b0180","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.ejpb.2014.01.009","article-title":"Rheological characterization and injection forces of concentrated protein formulations: an alternative predictive model for non-Newtonian solutions","volume":"87","author":"Allmendinger","year":"2014","journal-title":"Eur J Pharm Biopharm"},{"issue":"1\u20132","key":"10.1016\/j.ejpb.2021.06.001_b0185","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ijpharm.2015.04.019","article-title":"Effect of liposomes on rheological and syringeability properties of hyaluronic acid hydrogels intended for local injection of drugs","volume":"487","author":"El Kechai","year":"2015","journal-title":"Int J Pharm"},{"issue":"10","key":"10.1016\/j.ejpb.2021.06.001_b0190","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s11095-020-02906-9","article-title":"Tissue Resistance during Large-Volume Injections in Subcutaneous Tissue of Minipigs","volume":"37","author":"Allmendinger","year":"2020","journal-title":"Pharm Res"},{"issue":"8","key":"10.1016\/j.ejpb.2021.06.001_b0195","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1097\/IAE.0b013e3180592ba6","article-title":"Changes of intraocular pressure after intravitreal injection of bevacizumab (avastin)","volume":"27","author":"Falkenstein","year":"2007","journal-title":"Retina"},{"issue":"7","key":"10.1016\/j.ejpb.2021.06.001_b0200","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1111\/j.1600-0420.2007.00939.x","article-title":"Effect of intravitreal injections and volume changes on intraocular pressure: clinical results and biomechanical model","volume":"85","author":"Kotliar","year":"2007","journal-title":"Acta Ophthalmol Scand"},{"issue":"5","key":"10.1016\/j.ejpb.2021.06.001_b0205","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.exer.2005.03.014","article-title":"The pig eye as a novel model of glaucoma","volume":"81","author":"Ruiz-Ederra","year":"2005","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.ejpb.2021.06.001_b0210","article-title":"Correlation of tonometric and direct measurements of intraocular pressure in the porcine eye","volume":"46","author":"Yuan","year":"2005","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"8","key":"10.1016\/j.ejpb.2021.06.001_b0215","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.drudis.2019.03.017","article-title":"Causative glaucoma treatment: promising targets and delivery systems","volume":"24","author":"Mietzner","year":"2019","journal-title":"Drug Discov Today"}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641121001612?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641121001612?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:43:53Z","timestamp":1760546633000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641121001612"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":43,"alternative-id":["S0939641121001612"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2021.06.001","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intraocular pressure and injection forces during intravitreal injection into enucleated porcine eyes","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2021.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}